BURLINGTON, Mass. - Azenta, Inc. (NASDAQ: AZTA), a global provider of life sciences solutions, announced the election of ...

Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) ...

Azenta, Inc. (NASDAQ:AZTA), a company specializing in special industry machinery with a market capitalization of $2.46 billion, announced today that it has classified its B Medical (TASE:PMCN) Systems ...

Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday ...

Azenta, Inc. shares have surged over 30% since Nov 2024 due to S&P 600 inclusion and an analyst upgrade, despite somewhat ...

Evercore ISI raised the firm’s price target on Azenta (AZTA) to $50 from $48 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and ...

Azenta Life Sciences is committed to helping customers reach new heights in their pursuit of scientific progress. Discover enterprise-wide sample exploration and management solutions to accelerate ...

Azenta (AZTA) announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in ...

The UK Biocentre in Milton Keynes is set to enhance its large-scale biomedical research capabilities with the addition of a new high-density automated storage system. The BioArc Ultra, developed ...

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable ...